MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Search

Novartis AG

Deschisă

132.94 1.57

Rezumat

Modificarea prețului

24h

Curent

Minim

129.91

Maxim

132.45

Indicatori cheie

By Trading Economics

Venit

418M

4B

Vânzări

660M

14B

P/E

Medie Sector

18.012

35.739

EPS

2.42

Randament dividend

3.23

Marjă de profit

28.18

Angajați

75,883

EBITDA

-5.8B

4.9M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

-13.64% downside

Dividende

By Dow Jones

Randament dividend

Medie Sector

3.23%

3.08%

Statistici piață

By TradingEconomics

Capitalizare de piață

1.2B

240B

Deschiderea anterioară

131.37

Închiderea anterioară

132.94

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

Novartis AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

1 oct. 2025, 08:54 UTC

Principalele dinamici ale pieței

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

15 sept. 2025, 12:07 UTC

Principalele dinamici ale pieței

Monte Rosa Therapeutics Shares Soar on Drug Partnership with Novartis

9 sept. 2025, 10:11 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

Tourmaline Bio Shares Surge Premarket on Takeover by Novartis

9 sept. 2025, 05:52 UTC

Achiziții, Fuziuni, Preluări

Novartis Agrees to Buy Tourmaline Bio in $1.4 Billion-Dollar Deal

7 aug. 2025, 05:47 UTC

Achiziții, Fuziuni, Preluări

Novartis Makes Takeover Approach for Avidity Biosciences, FT Says, Citing Sources

17 iul. 2025, 14:26 UTC

Câștiguri

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- 2nd Update

17 iul. 2025, 06:49 UTC

Câștiguri

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- Update

17 iul. 2025, 05:41 UTC

Câștiguri

Novartis Lifts Profit Outlook After Growth in Sales, Earnings

1 oct. 2025, 06:47 UTC

Market Talk

Novartis Bags First FDA Approval for Rhapsido, More Could Follow -- Market Talk

29 sept. 2025, 11:46 UTC

Achiziții, Fuziuni, Preluări

Novartis: Offer to Expire Oct. 27

29 sept. 2025, 11:45 UTC

Achiziții, Fuziuni, Preluări

Novartis Has Started Tender Offer to Buy Tourmaline Bio

12 sept. 2025, 16:11 UTC

Câștiguri

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

9 sept. 2025, 08:09 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Novartis Makes Strategically Meaningful Move With Tourmaline Deal -- Market Talk

9 sept. 2025, 05:04 UTC

Achiziții, Fuziuni, Preluări

Novartis Offering $48 a Share for Tourmaline

9 sept. 2025, 05:04 UTC

Achiziții, Fuziuni, Preluări

Novartis: Offer Price Values Tourmaline at $1.4B on Fully Diluted Basis

9 sept. 2025, 05:03 UTC

Achiziții, Fuziuni, Preluări

Novartis to Buy Tourmaline Bio in Bid to Complement Cardiovascular Pipeline

9 sept. 2025, 05:00 UTC

Achiziții, Fuziuni, Preluări

Novartis to Buy Tourmaline Bio

11 aug. 2025, 11:16 UTC

Câștiguri

Rheinmetall, Ørsted, Novartis: Global Stocks in Focus -- WSJ

8 aug. 2025, 11:26 UTC

Market Talk

Novartis Is Getting Closer to Midterm Targets -- Market Talk

8 aug. 2025, 11:07 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Novartis Has Room to Accelerate Dealmaking -- Market Talk

8 aug. 2025, 10:51 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

5 aug. 2025, 10:40 UTC

Market Talk

Roche, Novartis Face Limited Tariff Headwinds for Now -- Market Talk

17 iul. 2025, 11:36 UTC

Market Talk

Novartis CEO Urges Europe to Reform Drug-Pricing System -- Market Talk

17 iul. 2025, 11:26 UTC

Market Talk

Novartis CEO Confident on Midterm Plan to Mitigate U.S. Tariff Hit -- Market Talk

17 iul. 2025, 07:14 UTC

Market Talk

Retirement of Well-Regarded Executive a Loss for Novartis -- Market Talk

17 iul. 2025, 07:02 UTC

Market Talk
Câștiguri

Novartis's Results Look Impressive -- Market Talk

17 iul. 2025, 05:09 UTC

Câștiguri

Novartis 2Q Sales Grew 11% at Constant Currency

17 iul. 2025, 05:08 UTC

Câștiguri

Novartis: Kirsch Will Continue as CFO, Member of Executive Committee Until March 2026

17 iul. 2025, 05:06 UTC

Câștiguri

Novartis: Mehta's Appointment Is Effective March 2026

17 iul. 2025, 05:05 UTC

Câștiguri

Novartis: Harry Kirsch Retires After 22 Years With Company

Comparație

Modificare preț

Novartis AG Așteptări

Obiectiv de preț

By TipRanks

-13.64% jos

Prognoză pe 12 luni

Medie 113.75 USD  -13.64%

Maxim 129 USD

Minim 100 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruNovartis AG - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

5 ratings

1

Cumpărare

3

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

N/A / 112.63Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Strong Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
help-icon Live chat